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INTRODUCTION
Infection with hepatitis B virus (HBV) may result in var-
ious conditions ranging from inactive healthy carrier to chronic
hepatitis, liver cirrhosis, and sometimes may progress to hep-
atocellular carcinoma (1). The reasons for this variation in the
natural history of HBV infection are unknown but are prob-
ably related to host immune factors. Chronic infection devel-
ops in approximately 5% of immunocompetent adults, but
up to 90% of newborns may become HBV carriers if the mo-
thers are seropositive for hepatitis B virus e antigen (HBeAg).
In hepatitis endemic area such as China and Korea, vertical
transmission is the most important cause of hepatitis B per-
sistence (2), but this cannot completely explain the persistence
of HBV infection.
Mannose-binding lectin (MBL) is an acute-phase protein
involved in activation of the classical complement pathway
(3). MBL acts as a direct opsonin by binding to collectin recep-
tors through its collagen domain (4). The middle surface pro-
tein of the HBV envelope contains a mannose-rich oligosac-
charide to which MBL could bind (5). MBL is an important
component of the human innate immune system and may
play a role in HBV infection.
To date three single nucleotide polymorphisms (SNPs) have
been well characterized in exon 1 at codons 52 (CGT→TGT),
codon 54 (GGC→GAC) and codon 57 (GGA→GAA), and
these differ considerably in their frequencies in different pop-
ulations (6). It is well known that MBL gene mutation leads
to low serum MBL level, which in turn makes affected indi-
viduals more prone to infection. SNPs in codon 54 and 57
of the MBL gene are related to low serum MBL levels (7). Sev-
eral investigators reported the association between MBL gene
polymorphism and HBV or hepatitis C virus (HCV) infection
(8-11). However, reports concerning the role of MBL in HBV
infections are conflicting. Furthermore, there are no data avail-
able regarding the prevalence of MBL gene SNPs in the Kore-
an population and the role of these SNPs in the natural course
of HBV infection.
Therefore, we have investigated the genotype frequencies
at codon 54 in the coding region of the MBL gene in Korean
patients with chronic hepatitis B, liver cirrhosis, and who
recovered infection, and have tried to find any association
between MBL gene SNPs and natural history of HBV infec-
tion.
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Lack of Association between Hepatitis B Virus Infection and 
Polymorphism of Mannose-Binding Lectin Gene in Korean Population
Mannose-binding lectin (MBL) plays an important role in immune defense. This
study was undertaken to investigate the association between hepatitis B virus infec-
tion and polymorphisms of MBL gene. We assessed the single nucleotide polymor-
phism at codon 54 in exon 1 of MBL in patients with hepatitis B virus infection and
HBsAg negative controls in Korean population. A total of 498 enrolled subjects was
classified into four groups. Group 1; Clearance, Group 2; Inactive healthy carrier,
Group 3; Chronic hepatitis, Group 4; Liver cirrhosis. MBL gene polymorphisms at
codon 54 led to three genotypes (G/G, G/A, A/A). When we divided subjects into
clearance group (group 1) and persistence group (group 2-4), G/G genotype and
A-allele carrier were observed in 55.6% and 44.4% in clearance group, 64.8% and
35.2% in persistence group (p=0.081), respectively. When hepatitis B virus persis-
tent cases were divided into inactive healthy carrier (group 2) and disease progres-
sion group (group 3 and 4), MBL gene polymorphisms at codon 54 were not relat-
ed to disease progression (p=0.166). MBL gene polymorphism at codon 54 was
not associated with the clearance of hepatitis B virus infection nor progression of
disease in chronic hepatitis B virus infection.
Key Words : Mannose-Binding Lectin; Hepatitis B; Polymorphism, Genetic
Received : 3 August 2004
Accepted : 6 September 200466 J.Y. Cheong, S.W. Cho, S.K. Lim, et al.
MATERIALS AND METHODS
Study subjects
Between March 2002 and September 2002, a total of 498
subjects was enrolled prospectively, from out-patient clinic
of the Gastroenterology Department of Ajou University Hos-
pital, Suwon, Korea. They were classified into four groups
according to the various status of HBV infection. Group 1;
HBV Clearance group [n=126, HBsAg (-), AntiHBc (+),
AntiHBs (+), who recovered from HBV infection], Group 2;
Inactive healthy carrier group [n=58, HBsAg (+) and HBeAg
(-), sustained normal transaminase level], Group 3; Chronic
hepatitis [n=239, HBsAg (+), elevated transaminase (≥2
times the upper limit of normal at least one time during the
follow-up period], Group 4; Liver cirrhosis [n=75, typical
morphologic findings on computed tomography/ultrasound
and corresponding laboratory features or evidence of portal
hypertension]. Among them, group 2, 3 and 4 were classi-
fied into ‘‘HBV persistence group’’.
The diagnostic criteria for chronic HBV infection were
seropositivity for HBsAg for more than 6 months, seroneg-
ativity for anti-HBs and presence of anti-HBc, and were fol-
lowed up for disease progression. Inactive healthy carrier and
chronic hepatitis patients had no evidence of portal hyperten-
sion and/or liver cirrhosis. None of enrolled patients had hep-
atocellular carcinoma. The chronic hepatitis (group 3) and
liver cirrhosis patients (group 4) were considered to have chron-
ic progressive liver disease, classified as ‘‘progressive group’’
when compared with inactive healthy carriers (group 2).
Patients who were positive for anti-HBs and negative for
anti-HBc IgG (vaccinated subjects), and patients with other
types of chronic liver disease such as alcoholic liver disease,
chronic hepatitis C, steatohepatitis, Wilson’s disease, were ex-
cluded from this study. All the subjects were Korean, a single
ethnic population. Informed consents were obtained from each
subject, and the Institutional Review Board of Human Rese-
arch of Ajou University Hospital approved the study protocol.
MBL Genotyping
Before the analysis, we tested MBL gene polymorphism
at codon 52, 54 and 57 in 100 healthy Korean populations.
In this pilot assay, we could not find any polymorphism at
codon 52 and codon 57 in Korean population. The only MBL
gene SNP found in our Korean population was that at codon
54 of exon 1. MBL gene polymorphism was identified only
at codon 54 (Glycine→Aspartate, GGC→GAC), leading
to three genotype (G/G, G/A, A/A genotype). Therefore, we
assessed the genetic polymorphism at codon 54 of MBL in
372 patients with HBV infection, and in 126 HBsAg nega-
tive controls who had eliminated HBV.
Genomic DNA was extracted from 300  L whole blood
using a DNA Purification kit (GENTRA, Minneapolis, MN,
U.S.A.) according to the manufacturer’s instructions. The SNP
of MBL gene codon 54 was detected by polymerase chain
reaction (PCR) amplification. The parameters for thermocy-
cling were as follows: An initial activation step of 95℃ for
10 min preceded the cycling program; followed by 35 cycles
of denaturation at 95℃; annealing at 72℃ for 1 min; and
final extension at 72℃ for 7 min. Each PCR products were
purified by a Qiagen PCR purification kit, and the polymor-
phisms were detected by single base primer extension assay
(SNP ITTM). Briefly, the assay is to anneal a detection primer
to the nucleic acid sequence immediately 3′ of the nucleotide
position to be analyzed and to extend this primer with a single
labeled nucleoside triphosphate that is complementary to the
nucleotide to be detected using a DNA polymerase.
Statistical analysis
For univariate analysis,  2 test was used for Hardy-Wein-
berg equilibrium of alleles at MBL gene loci and independent
sample t test for normally distributed continuous variables.
The analysis was carried out using the statistical computer
software SPSS11.0/Windows (SPSS Inc., Chicago, IL). All p
values were two-tailed, and p value <0.05 was considered to
indicate statistical significance throughout the study. 
RESULTS
Demographic characteristics of the subjects with HBV clear-
ance vs. persistence groups and inactive carrier vs. progression
Total (n=498) Clearance (n=126) Persistence (n=372) p Inactive carrier (n=58) Progression (n=314) p
Age (mean±SD) 47.86±9.38 39.68±9.98 0.000 42.22±12.44 39.21±9.40 NS
Sex (M:F) 89:37 281:91 NS 32:26 249:65 0.000
AFP (ng/mL, mean±SD) 2.48±1.58 15.58±52.20 0.023 2.68±3.14 18.09±56.72 0.002
Platelet (×10
3/ L, mean±SD) 256.79±60.77 181.41±64.34 0.000 214.13±70.70 175.71±61.54 0.000
AST (U/L, mean±SD) 36.29±73.78 69.50±102.46 0.001 28.60±7.50 77.05±109.85 0.000
ALT (U/L, mean) 35.29±29.03 90.78±124.77 0.000 32.93±16.98 101.47±132.91 0.000
Bilirubin (mg/dL, mean) 0.843±0.398 1.084±1.658 NS 0.802±0.280 1.134±1.793 NS
Albumin (g/dL, mean) 4.408±0.265 4.281±1.223 NS 4.289±0.585 4.280±1.306 NS
Table 1. Demographic characteristics of patients
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groups, were shown in Table 1. Differences between clearance
and persistence groups in aspartate transaminase/alanine trans-
aminase (AST/ALT), platelet, alpha-fetoprotein (AFP) were
observed. The serum levels of AST, ALT, AFP at baseline were
significantly higher in HBV persistence group. The platelet
count was lower in HBV persistence group. Age was younger
in persistence group, but no significant differences in the dis-
tributions of their gender were detected between clearance
group and persistence group. Concerning the comparison of
inactive carrier and HBV progression group, male sex was
the risk factor for HBV progression, but there was no differ-
ence in age distribution.
Genotype data were complete for the MBL gene markers
in all of the subjects. The frequencies of the genotypes of the
MBL codon 54 in enrolled patients are summarized in Table
2. Allelic frequencies in codon 54 of MBL gene are as follows.
In group 1, G/G genotype was 55.6% of patients, G/A geno-
type was 41.3%, A/A genotype was 3.2%. In group 2, G/G,
G/A, A/A genotype frequencies were 67.2%, 29.3% and
3.4%, respectively. In group 3, G/G, G/A, A/A genotype
frequencies were 63.6%, 32.6% and 3.8%, respectively. In
group 4, G/G, G/A, A/A genotype frequencies were 66.7%,
32.0% and 1.3%.
Associations between MBL gene SNPs at codon 54 and
HBV clearance
MBL gene SNPs at codon 54 were analyzed in patients with
chronic HBV infection (‘‘persistence’’) and healthy individuals
who recovered from HBV infection (‘‘clearance’’) (Table 3).
Since specific MBL genotype has been linked to MBL protein
production and phenotype, we repeated the analysis of data
comparing G/G genotype and A-allele carrier among the dif-
ferent groups. The frequencies of G/G genotype and A-allele
carrier (G/A, A/A) were observed in 55.6% and 44.4% in
HBV clearance group, 64.8% and 35.2% in persistence gr-
oup. Comparison of genotype frequencies showed no signif-
icant differences between the clearance and persistence group
(p=0.081).
Associations between MBL gene SNPs and HBV disease
progression
We evaluated whether MBL gene polymorphism is related
to disease progression in HBV infection by comparing the
genotype frequency between inactive carriers (group 2) and
progressive group (group 3 and 4). No significant differences
were detected between two groups in the distributions of MBL
gene genotype at codon 54 (G/G:67.2%, A allele carrier:32.8
% in HBV healthy carrier, G/G:64.3%, A-carrier:35.7% in
HBV progression group) (p=0.166) (Table 4).
DISCUSSION
The persistent HBV infection is a major public health prob-
lem, particularly in the hepatitis endemic areas such as Korea,
Taiwan and China (12). Elimination of HBV after infection
depends on the activities of the patients’ immune systems. It
is well established that several host factors, including age at
the time of infection, sex, immune status and possibly ethnic
origin, are important in promoting development of chronic
hepatitis B infection. These factors may have confounding
impacts on this study. The family history of HBV infection was
not completely evaluated and it was hard to presume the onset
of HBV infection. Therefore, we were not able to compare the
effect of the polymorphism on the risk for chronic HBV infec-
tion to that of the age at which the subject is infected. How-
ever, considering the finding that perinatal or early childhood
infections of HBV, particularly mother-to-child transmission
of the virus, is the most common source of chronic infection
in the endemic area, most HBV persistent subjects in this
study are considered to be infected in this manner. Moreover,
our study included single ethnic population. Therefore, we
have minimized the confounding factors affecting the course
*, chronic progressive liver disease: chronic hepatitis and liver cirrhosis.
Genotype
Clearance
(n=126)
Inactive carrier
(n=58)
Chronic progressive 
liver disease*
(n=314)
G/G 70 (55.6%) 39 (67.2%) 202 (64.3%)
G/A 52 (41.3%) 17 (29.3%) 102 (32.5%)
A/A 4 (3.2%) 2 (3.4%) 10 (3.2%)
Table 2. Genotype frequencies in MBL gene codon 54 in enrolled
subjects
Genotype
Clearance
(n=126)
Persistence
(n=372)
p value
G/G, G/A, A/A 0.167
G/G 70 (55.6%) 241 (64.8%)
G/A 52 (41.3%) 119 (32.0%)
A/A 4 (3.2%) 12 (3.2%)
G/G, A carrier 0.081
G/G 70 (55.6%) 241 (64.8%)
A carrier 56 (44.4%) 131 (35.2%)
Table 3. MBL gene polymorphism and HBV persistence
Genotype
Inactive carrier
(n=58)
Progressive
(n=314)
p value
G/G, G/A, A/A 0.424
G/G 39 (67.2%) 202 (64.3%)
G/A 17 (29.3%) 102 (32.5%)
A/A 2 (3.4%) 10 (3.2%)
G/G, A carrier 0.166
G/G 39 (67.2%) 202 (64.3%)
A carrier 19 (32.8%) 112 (35.7%)
Table 4. MBL gene polymorphism and HBV disease progression68 J.Y. Cheong, S.W. Cho, S.K. Lim, et al.
of HBV infection.
The host genetic factors involving genetic polymorphisms
are reported to play a key role in influencing clinical outcomes
of infectious disease. A number of studies have identified poly-
morphisms that influence susceptibility to persistent HBV
infection (9, 13, 14). Previous reports suggest that DRB1*
1301 and *1302 allele are both protective against develop-
ment of chronic HBV infection (15). A protective effect of
DRB1*1301, *1302 against the development of HBV per-
sistence has been suggested in a study on an ethnically hetero-
geneous group of west Africans (13). Cytokine polymorphisms
such as tumor necrosis factor- (TNF- ) or interleukin-10
(IL-10) were investigated. Recently, Kim et al. reported that
TNF- promoter allele associated with higher-plasma TNF-
levels was strongly associated with the resolution of HBV
infection in Korean population (14).
MBL is a Ca2+ dependent serum lectin specific for mannose
and N-acetylglucosamine (4). MBL has been known to have
an important role in innate immunity and has been shown
to have complement dependent bactericidal activity (3). The
middle envelope protein of HBV has an asparagine residue at
position 4. This residue is glycosylated with an oligosaccha-
ride, which is, in part, mannose-terminated. Therefore, opso-
nization of viral particle by normal serum MBL is possible.
MBL serum levels are profoundly reduced by polymor-
phisms in the coding region of the MBL gene (7). Concern-
ing the relationship between natural history of HBV infec-
tion and MBL gene SNPs, many reports showed conflicting
results. Yuen et al. showed that codon 54 mutation of MBL
gene was associated with progression of disease in chronic
hepatitis B infection in Chinese population. According to
their reports, in patients with decompensated cirrhosis, the
codon 54 mutation rate was greatly increased. And they found
that spontaneous bacterial peritonitis (SBP) patients had
marked increase in codon 54 mutation rate and decrease in
serum MBL level when compared with those without SBP
(8). In Caucasian population, mutant allele at codon 52 of
MBL gene was reported to be associated with chronic hep-
atitis B infection. But, they failed to reveal the association
between SNP at codon 52 and HBV persistence in Asian
population. Furthermore, there was no association of the codon
54 or codon 57 mutant alleles with acute or chronic hepatitis
B (11). Therefore, the role of MBL in the outcome of HBV
infection still remains unclear.
Our study demonstrated that the SNP at the second posi-
tion of codon 54 of MBL was not associated with HBV per-
sistence. This result was consistent with the previous report,
which showed that this polymorphism have no association
with HBV clearance (16). We included more than 100 indi-
viduals who were completely recovered from HBV infection
as control. Furthermore, we believe that the controls in our
study were more relevant to evaluate the role of host genetic
factor in determining viral clearance of HBV.
We found no association of MBL gene SNP at codon 54
with disease progression. There are a few studies suggesting
the relationship of the polymorphism with the disease pro-
gression of HBV infection (8). In the present study, the num-
ber of subjects with A/A genotypes at codon 54 of MBL gene
was limited, so we had difficulty in assessing any possible
association between the genotypes and clinical features. Such
ethnic differences in the distribution of the polymorphisms
may account for the lack of the correlation in our study, which
was not in agreement with other studies. In addition, the
number of the patients who undergone liver biopsy during
the study period was limited in the study so that we might
under- or overestimate the stage of disease progression in some
of patients with chronic HBV infection. It might miss pos-
sible association between the polymorphisms and disease pro-
gression in HBV infection.
Although several studies have suggested that the MBL gene
SNP alter MBL production, it was mostly based on in vitro
experiments. The results would be different according to the
type of the stimuli or experimental conditions. MBL expres-
sion may also be disease stage-specific, and serum levels may
not necessarily correlate with the local MBL levels in liver.
Further studies are needed to evaluate the exact functional
consequences of MBL polymorphisms on MBL level in both
peripheral blood and liver cells at various stages of disease
progression.
In conclusion, this study suggested that polymorphism at
codon 54 of MBL gene is not associated with HBV clearance
nor disease progression in Korean population. Further studies
should continue to address the effect of these polymorphisms
on HBV infection.
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